Med

Med is published by Elsevier and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, SARS-CoV-2 and COVID-19 Research and CAR-T cell therapy research, together about 27.9% of its articles. (generated from OpenAlex topic counts and CAS ranking data)

Med is a flagship clinical and translational research monthly journal published by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Chem, and Joule. Our mission is to accelerate translation of bench research to the clinic by providing a communication forum for the exchange of knowledge, fresh ideas, and thought-leadership among translational researchers, clinicians, and Biotech and Pharma scientists as well as other medical research stakeholders. Our goal is to sustainably and ethically improve health globally.Med publishes rigorously vetted original research and state-of-the-art Review and Perspective articles across the translational and clinical continuum. Our translational research articles are deeply rooted in understanding disease mechanisms, with demonstrable functional impact and broad transformative insights. Our clinical studies cover case reports, first-in-human studies, and large-scale clinical trials, including phase IV, which have the potential to change the course of medical research and improve clinical practice.We are interested in research with likely immediate impact on clinical therapy. These include clinical studies, translational research papers addressing disease mechanism and/or therapies, biotechnology and engineering advances with important clinical impact, and resources (such as informational databases) of broad medical utility. Topics of interest for the journal include but are not limited to:Aging and health-span interventions: sarcopenia; senescence and senolytic treatments; dietary interventions; hormonal disordersBiomedical engineering – new device optimization and diagnostic toolsCancer: immuno-oncology; tumor evolution and cancer genetics; surgery and therapeutic modalitiesCardiovascular and metabolic disease: heart disease; diabetes; obesity; NAFLD/NASHGenetics and cell-based therapies: medical genomics; CRISPR-based; RNAi; stem cells; organoids; transplantationHealth economics and public policy: global challenges; health access; public health interventions; clinical practicesHuman microbiome: mechanistic studies of the human microbiomes impact on diseaseImmunology: allergy and inflammation; autoimmunity; innate immunity; graft-versus host disease; vaccinologyInfectious diseases: HIV/AIDS; SARS; ebola; other bacterial, viral, fungal, or parasitic infections; infectious diseases epidemiology; antimicrobials and resistanceNeurology: Alzheimers disease; dementia; cognitive dysfunctions; brain-vascular dysfunction; Parkinsons and movement disorders; amyotrophic lateral sclerosis; depression; neuroengineering therapies

From the journal's Aims & Scope

Research area (LetPub): MEDICINE, RESEARCH & EXPERIMENTAL

CAS Journal Ranking

Database indexing

ESCIScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor (publisher)

13.3Publisher website · 2026-09-30

CiteScore 2026-06

15.1LetPub · 2026-09-13

CiteScore (publisher)

15.1Publisher website · 2026-09-30

SJR 2026-06

4.34LetPub · 2026-09-13

SNIP 2026-06

2.02LetPub · 2026-09-13

h-index

67OpenAlex · 2026-10-01

i10-index

317OpenAlex · 2026-10-01

2-year mean citedness

9.14OpenAlex · 2026-10-01

Self-citation rate

0.8%LetPub · 2026-09-13

Share of gold OA articles

36.65%LetPub · 2026-09-13

Volume

Articles per year

116LetPub · 2026-09-13

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Submission to first decision

2 daysPublisher website · 2026-09-30

Submission to acceptance

64 daysPublisher website · 2026-09-30

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Elsevier

ISSN

2666-6340

Print ISSN

2666-6359

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗Publisher website
• Special issues ↗Publisher website